Business Wire

ByteDance Purchases more than 100,000 Units of Rubicon Carbon’s Flagship Product, The Rubicon Carbon Tonne ®

25.6.2025 14:00:00 CEST | Business Wire | Press Release

Share

Rubicon Carbon, a leading carbon credit management firm, announced today that ByteDance, the global technology company behind content platforms including TikTok, has purchased the right to retire more than 100,000 tonnes of carbon credits. The credits were purchased through Rubicon Carbon’s flagship carbon credit offering, the Rubicon Carbon Tonne® (RCT), and represent a milestone on ByteDance’s path toward achieving its carbon neutrality target by 2030 while also underscoring the company’s commitment to high-integrity climate action.

Rubicon Carbon Tonnes (RCTs) are actively managed portfolios of high-quality carbon credits from global projects, including nature-based, super pollutant, and carbon removal initiatives. Rubicon’s science team ensures ongoing monitoring and integrity. Buyers secure access to premium credits at today’s prices, reducing exposure to future cost spikes and supply issues. With expert management, RCTs offer confidence that retired credits will meet the highest standards and deliver measurable climate impact.

The RCTs acquired by ByteDance include a carefully curated mix of nature-based avoidance credits and carbon removal credits designed to deliver both immediate climate impact and long-term carbon dioxide removal.

“We are thrilled to welcome ByteDance as a buyer of Rubicon Carbon Tonnes,” said Tom Montag, CEO of Rubicon Carbon. “ByteDance’s decision to invest in RCTs signals a serious, long-term commitment to climate leadership and a recognition that the path to net zero must be built on high-quality, durable carbon solutions. We're proud to play a role in helping them meet that goal.”

To achieve its carbon neutrality goals by 2030, ByteDance aims to reduce at least 90% of its operational emissions, with the remaining 10% offset by carbon credits. Rubicon Carbon’s team provided ByteDance with robust educational resources and advisory support, helping the company evaluate its purchases in the voluntary carbon market with confidence.

“We greatly appreciate the time and expertise that the Rubicon Carbon team invested to help us make high-value and impactful decisions within the carbon credit landscape,” said Ian Gill, Global Head of Sustainability at ByteDance. “As we advance toward our 2030 carbon neutrality goal, it’s critical that we build long-term relationships with trusted partners. This purchase marks an important step in that journey, and we look forward to continuing our collaboration with Rubicon Carbon.”

The announcement builds on Rubicon Carbon’s continued momentum as a trusted partner to global organizations seeking scalable, science-based climate solutions. The company’s unique approach to carbon credit sourcing — combining rigorous project selection with a portfolio-based structure — ensures that every Rubicon Carbon Tonne meets the highest standards of environmental integrity.

For more information about Rubicon Carbon and the Rubicon Carbon Tonne, visit rubiconcarbon.com.

About Rubicon Carbon:
Rubicon Carbon is a carbon credit management firm that empowers the world’s largest enterprises to achieve their sustainability goals by addressing carbon emissions and driving global climate finance. Backed by TPG Rise Climate and led by top executives from across finance, technology, and climate science, Rubicon Carbon delivers innovative carbon credit solutions to global businesses while unlocking carbon avoidance and removal projects at scale, all backed by rigorous in-house scientific diligence. For more information, visit www.rubiconcarbon.com.

About ByteDance:
Founded in 2012, ByteDance's mission is to inspire creativity and enrich life. With a suite of more than a dozen products, including TikTok, Helo, and Resso, as well as platforms specific to the Chinese market, including Toutiao, Douyin, and Xigua, ByteDance has made it easier and more fun for people to connect with, consume, and create content. ByteDance's investors include Coatue, General Atlantic, KKR, Sequoia Capital, SIG, and Softbank.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250625148017/en/

Contacts

Rubicon Carbon Media Relations
rubiconcarbon@berlinrosen.com
+1 (714) 300-8748

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye